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Visceral leishmaniasis (VL), or kala-azar, the 
most severe form of leishmanial disease, is a 
chronic infectious disease characterized by   fever, 
enlargement of the spleen and liver, weight 
loss, anemia, and leucopenia. If left   untreated, 
VL is generally fatal. Most cases of kala-azar 
  occur in India, Sudan, Nepal, and Bangladesh, 
where it is caused by the trans  mission of Leish-
mania donovani. Every year, >100,000 cases of 
VL occur in India alone, with the state of Bihar 
accounting for the   majority of these cases, 
  followed by West Bengal and Eastern Uttar 
Pradesh. Pentavalent antimonial compounds 
(Sbv) have remained the fi  rst-line treatment 
for VL in most endemic regions. In Bihar, 
however, there has been a growing incidence 
of refractoriness to Sbv, such that infusion with 
amphotericin B remains the only option avail-
able to most patients (1). Overall, treatment 
of VL remains unsatisfactory, and there is an 
  urgent need to develop new therapies to re-
duce drug toxicity and long-term hospitali-
zation, and to prevent drug resistance. As 
successful treatment of kala-azar is thought to 
depend, at least in part, on alterations in the 
host immune response to the parasite, direct 
manipulation of the immune response, either 
alone or in combination with drugs, may be 
a useful strategy for improving treatment   regimens 
for VL.
A key immunologic feature of   VL is the in-
ability of PBMCs to mount curative, antigen-
specifi  c immune responses (2, 3), as refl  ected by 
their failure to proliferate or to produce IFN-γ 
in response to leishmanial antigens. There 
  appears to be no inherent defect in antigen-
  induced Th1 responsiveness, however, because 
cured individuals are resistant to reinfection, 
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Visceral leishmaniasis (VL) is a life-threatening disease characterized by uncontrolled 
parasitization of the spleen, liver, and bone marrow. Interleukin (IL)-10 has been impli-
cated in the suppression of host immunity in human VL based on the elevated levels of 
IL-10 observed in plasma and lesional tissue, and its role in preventing clearance of 
Leishmania donovani in murine models of VL. The aim of this study was to identify the 
cellular source of IL-10 in human VL and determine if CD4+CD25+ (Foxp3high) regulatory 
T (T reg) cells are associated with active disease. We analyzed surface marker and gene 
expression in peripheral blood mononuclear cells and splenic aspirates from Indian VL 
patients before and 3–4 wk after treatment with Amphotericin B. The results did not 
point to an important role for natural CD4+CD25+ (Foxp3high) T reg cells in human VL. 
They did not accumulate in and were not a major source of IL-10 in the spleen, and their 
removal did not rescue antigen-specifi  c interferon 𝗄 responses. In contrast, splenic T cells 
depleted of CD25+ cells expressed the highest levels of IL-10 mRNA and were the pre-
dominant lymphocyte population in the VL spleen. The elevated levels of IL-10 in VL 
plasma signifi  cantly enhanced the growth of L. donovani amastigotes in human macro-
phages. The data implicate IL-10–producing CD25−Foxp3− T cells in the pathogenesis 
of human VL.
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become leishmanin skin test positive, and mount antigen-
  specifi  c IFN-γ responses in vitro (4, 5). Furthermore, even 
during the acute phase of   disease, elevated levels of IFN-γ 
mRNA have been found in lesional tissue, such as the spleen 
and bone marrow (6–8).
The regulatory cytokine, IL-10, has repeatedly been 
  implicated as an immunosuppressive factor in both human 
and experimental leishmaniasis. Patients with an advanced 
stage of disease have elevated levels of IL-10 in serum (9, 10) 
as well as enhanced IL-10 gene expression in lesional tissue 
(6–8). In mice, IL-10–defi  cient BALB/c and C57BL6 mice 
are highly resistant to L. donovani infection, and treatment of 
wild-type mice with anti–IL-10 receptor anti  body promotes 
rapid control of L. donovani infection and dramatically en-
hances the leishmanicidal activity of Sbv (11–13).
IL-10 has pleiotropic, primarily deactivating eff  ects on 
target cells, including antagonizing dendritic cell functions 
and rendering macrophages unresponsive to activation 
  signals (14). Importantly, the source(s) of IL-10 in human 
VL has not been defi  ned. IL-10 can be produced by many 
cell types, including B cells, macrophages, and CD4+ T cells 
(14). Several IL-10–producing CD4+ T cell subpopulations 
have been described that have in common their ability to 
inhibit the response of other T cells (15, 16). The best char-
acterized regulatory CD4+ T cell subset is defi  ned by its 
constitutive expression of IL-2R-α chain (CD25) and by 
expression of the transcriptional regulator Foxp3. Naturally 
occurring CD4+CD25+Foxp3+ regulatory T (T reg) cells 
constitute 5–10% of peripheral CD4+ T cells in naive mice 
and humans, and suppress several potentially tissue-damaging 
responses in vivo, most notably T cell responses directed 
against self-antigens. T reg cells may also suppress poten-
tially benefi  cial immune responses, such as those directed 
against tumors and microbial pathogens. Naturally occur-
ring T reg cells have been shown to produce high amounts 
of IL-10 and/or TGF-β, which in some experimental 
  systems is responsible for their suppressive activity in vivo. 
Experimental models of cutaneous leishmaniasis have shown 
that IL-10 produced by naturally occurring T reg cells is 
crucial for persistent Leishmania major infection (17). In 
  humans, dysregulation in the equilibrium between natural 
T reg cells and eff  ector T cells has been associated with 
  impaired immune responses to chronic infections, such as 
  Helicobacter pylori, hepatitis C virus, and HIV (18–20), and 
depletion of CD4+CD25+ cells from PBMCs has been 
shown to increase antigen-specifi  c proliferative and IFN-γ 
responses against several microbial antigens (21–23). Fi-
nally, T reg cells from hepatitis C virus patients have been 
demonstrated to be a source of antigen-specifi  c IL-10 (22). 
The   objective of the present study was to reveal the cellular 
source of the elevated IL-10 in VL, to determine whether ac-
cumulation or activation of T reg cells is associated with VL 
pathology, and to demonstrate an immunosuppressive role 
for IL-10.
Figure 1.  Cytokines in plasma from VL patients. Multiplex analysis 
of cytokines in plasma of VL patients before treatment (n = 18) and ECs 
(n = 17). 10 samples from each group were used for IL-12p70 analysis. 
Signifi  cant differences are indicated with p-values using Student’s t test 
or Mann-Whitney U-test, when a normality test failed (IL-4 and 
IL-12p40).JEM VOL. 204, April 16, 2007  807
ARTICLE
RESULTS
Active VL is associated with elevated plasma levels 
of multiple cytokines
Screening of plasma using a multiplex assay showed that VL 
patients (see Table I) had elevated levels of circulating IL-2, 
IL-4, IL-6, IL-10, IL-12p40, IL-12p70, IL-13, IFN-γ, and 
TNF-α (Fig. 1). There was no diff  erence in total TGF-β 
  between the groups (not depicted). Thus, it would appear that 
Th1- and Th2-inducing as well as suppressive signals are in-
duced in VL. The diff  erence between VL patients and endemic 
controls (ECs) was especially striking in the levels of plasma 
IL-10, which was elevated in 15 of the 18 VL patients studied, 
but barely detectable in all 17 of the ECs.
Plasma IL-10 from VL patients promotes intracellular 
growth of L. donovani in human macrophages
The comparison of L. donovani infection levels in macro-
phages from a single normal human donor after a 3-d incu-
bation in 20% plasma from VL patients or ECs, and in the 
presence of anti–human IL-10 or isotype control antibodies, 
is shown in Fig. 2. Neutralization of IL-10 resulted in reduced 
numbers of intracellular amastigotes in all cultures containing 
the plasma from the 13 diff  erent VL patients tested, and the 
mean infection levels in the anti–IL-10–treated VL group 
was signifi  cantly reduced compared with the control-treated 
group (P < 0.001). In contrast, no signifi  cant diff  erence in 
infection levels was observed after neutralization of IL-10 
in cultures containing plasma from any of the six ECs tested, 
and the mean number of organisms was comparable to that 
observed after culture in the VL plasma treated with anti–
IL-10. The ability of recombinant human IL-10 to promote 
L. donovani infection in these macrophages is also shown, 
and the ability of the anti–IL-10 to neutralize this eff  ect is 
confi  rmed. Thus, the elevated levels of circulating IL-10 in VL 
patients detected by the multiplex assay can be shown to have 
a direct eff  ect on enhancing infection. It is important to 
note that because the VL plasma was added after the uptake of 
amastigotes and removal of any remaining extracellular para-
sites, it is unlikely that the source of IL-10 in these cultures 
was from macrophages after activation by immune complexes, 
as has been described (24).
PBMC profi  le in VL patients and ECs
Assessment of surface marker expression on gated PBMC 
lymphocytes (see Table II) showed no diff  erences between VL 
patients and ECs in the percentage of cells expressing CD3, 
CD4, CD8, or CD19, nor any changes in B cell/T cell or 
CD4/CD8 T cell ratios. In line with previous reports (25, 26), 
alterations in the CD4 lymphocytes CD45RA/RO ratio 
were evident, which suggested a reduction in the percentage 
of memory (CD45RO) CD4 cells in VL patients. Expression 
of NK cell–associated markers NKp46 and CD16 was slightly 
lower in VL patients compared with ECs, but the frequency 
of CD3−CD56+ did not diff  er.
Figure 2.  IL-10 in plasma from VL patients enhances L. donovani 
growth in human macrophages. Monocyte-derived macrophages from 
a normal human donor were infected with L. donovani amastigotes for 6 h, 
and after the removal of extracellular parasites, cultures were incubated 
for an additional 72 h in the presence of 20% plasma from VL   patients 
or ECs, and treated with either anti–IL-10 or isotype control antibodies. 
Infected macrophages cultured in 20% normal human AB serum and 
treated with recombinant human IL-10 plus anti–IL-10 or control anti-
bodies are also shown, as is the control of infected macrophages cultured 
in AB serum alone (□). Symbols shown represent the mean of duplicate 
assays, and bars designate the means for each treatment group.
Figure 3.  Natural T reg cells in PBMCs from VL patients. Analysis 
of T reg cells in PBMCs from VL patients (pretreatment) and ECs. (A) Per-
centage CD4+CD25+ of gated T (CD3+) lymphocytes (n = 22/23). 
(B) Percentage CD25+CD45RO+ cells of gated CD4+ lymphocytes (n = 22/23). 
Relative Foxp3 mRNA expression in (C) whole PBMCs (n = 12/10) and 
(D) positively selected CD25+ cells (n = 6) and CD25-depleted PBMC 
 populations  (n = 6). Donors analyzed were the same in A and B, but not 
in C and D. Signifi  cant differences are indicated with p-values using 
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Regulatory CD4+CD25+ (Foxp3) T cells in PBMCs 
of VL patients and ECs
Analysis of the percentage of T cells expressing surface mark-
ers CD4+CD25+ in PBMCs revealed no diff  erence between 
VL patients and ECs (Fig. 3 A). Because in the mouse natural 
CD4+CD25+ T reg cells are also CD45RBlow, a comparable defi  -
nition of human T reg cells as CD4+CD25+CD45RO+RA− 
indicated a frequency slightly lower in pretreatment VL 
PBMCs compared with ECs (P = 0.013; Fig. 3 B). Analysis 
of Foxp3 mRNA supported this fi  nding, again showing a 
slightly lower expression in whole PBMCs from VL patients 
compared with ECs (P = 0.0487; Fig. 3 C). Analysis of Foxp3 
expression in positively selected CD25+ cells showed that, 
  although highly enriched in this population, there was no 
  diff  erence between the level of Foxp3 mRNA in VL patients 
and ECs when normalized for comparable numbers of cells, 
nor was there a diff  erence in Foxp3 expression in the CD25-
depleted PBMCs (Fig. 3 D).
Depletion of CD25+ cells does not rescue 
Leishmania-specifi  c PBMC responses
To test if T reg cells mediated the antigen-specifi  c unrespon-
siveness observed in PBMCs from VL patients, we evaluated 
the eff  ect of CD25 depletion on IFN-γ and IL-10 secretion 
by PBMCs in 3-d culture supernatants after stimulation with 
staphylococcal enterotoxin B (SEB) or soluble L. donovani 
  antigen (SLA; Fig. 4). Consistent with prior observations, 
PBMCs from VL patients did not respond to stimulation with 
leishmanial antigen, whereas  30% of the ECs produced 
IFN-γ in response to SLA, again consistent with prior studies 
involving family members of active cases in Bihar (3). The 
  response of VL PBMCs to the superantigen SEB remained 
  intact. With the exception of one patient, SLA-specifi  c IFN-γ 
responses in VL PBMCs were not revealed by removal of 
CD25+ cells. The IFN-γ responses to SEB were signifi  cantly 
enhanced in CD25-depleted EC-PBMCs (9 of 12 donors), 
which validates the depleted CD25+ cells as functional 
  suppressors of an eff  ector response. Interestingly, removal of 
CD25+ cells from VL PBMCs enhanced SEB-induced IFN-γ 
secretion in only two patients. Detectable IL-10 secretion was 
only induced by SEB stimulation, and removal of CD25+ cells 
strongly reduced IL-10 production by the EC-PBMCs (Fig. 4, 
C and D), validating these cells as a potential source of IL-10. 
Moreover, activation of CD25-depleted T cells for proliferation 
or IFN-γ production could not be induced by co-culture 
with CD14-derived dendritic cells stimulated with SLA or 
live stationary phase promastigotes (not depicted). Based on 
these results, the inability of PBMCs to respond to leishmanial 
antigen is unlikely to be mediated by T reg cells. If anything, 
these cells appear to be somewhat reduced in both frequency 
and suppressive activity in PBMCs from VL patients.
We also made repeated attempts to recover Leishmania-
specifi  c proliferative and IFN-γ responses by blocking IL- 10. 
However, in line with the fi  nding that no IL-10 could be 
measured over background in antigen-stimulated cultures, no 
eff  ect of the blocking antibodies was observed. IL-10 blockade 
was only eff  ective in the SEB-stimulated cultures in which 
IL-10 induction was also observed (not depicted).
Figure 4.  Cytokine production by whole or CD25-depleted PBMCs 
in response to SEB or SLA. IFN-γ (A and B) and IL-10 (C and D) in 
three-dimensional culture supernatant from whole or CD25-depleted 
PBMCs isolated from EC (n = 12; A and C) or VL patients before treat-
ment (n = 11; B and D).JEM VOL. 204, April 16, 2007  809
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Lymphocyte profi  le in human spleen samples
To address the possibility that T reg cells are recruited to and 
accumulate in target organs, we undertook a comprehensive 
analysis of the frequency and cytokine profi  les of lymphocyte 
subsets in VL spleens before and after curative treatment with 
amphotericin B and in comparison with splenic cells from 
healthy organ donors (HODs). To our knowledge, this is the 
fi  rst fl  ow cytometry–based analysis of lymphocyte popula-
tions in VL spleen before and after treatment, and the fi  rst to 
conduct cytokine mRNA expression analysis on defi  ned sub-
sets of splenic cells. As only 50–200 μl of aspirated tissue, 
containing  0.5–3 × 106 (median 1.7 × 106) white cells, was 
available for analysis, the spleen cells were processed either for 
FACS analysis or real-time PCR, but not both. Diff  erential 
counting of stained splenic smears indicated that the major-
ity (70%) of the nucleated cells were lymphocytes, 4% were 
plasma cells, 7% were monocytes/macrophages, and 10% were 
neutrophils. Blast morphology was frequently observed; thus, 
a broad gate was used for FACS analysis of lymphocyte   subsets 
(Fig. 5 A). Based on profi  les of PBMCs or whole blood, and 
on back-gating of analyzed samples and subsequent   annexin 
V–7ADD (apoptotic: dead) staining of splenic aspirates (not 
depicted), the cells gated on forward-side scatter were mainly 
viable lymphocytes (small and blast), but also included most of 
the CD14+ monocytes present in the aspirate. Cells/events 
scattered to the left of the gate are RBCs, debris, and a few 
dead cells. Granulocytes were scattered above the gate.
Commonly used lymphocyte surface markers were assessed 
in the aspirates from patients with active VL and compared 
with posttreatment samples and healthy spleen cells obtained 
from HODs (Fig. 5, B–G). The most striking change in the VL 
spleen was the B cell (CD19)/T cell (CD 3) ratio, which 
  implicated splenic T cell infi  ltration/proliferation and/or se-
lective loss or diff  erentiation of B cells during active VL. 3 wk 
after initiation of treatment, an increase in the B/T cell ratio 
could already be observed, concomitant with a decrease in 
Figure 5.  Flow cytometry analysis of lymphocyte subsets in VL. 
(A) Forward (linear) side (log) scatter profi  les of splenic aspirates from the 
same VL patient before and after treatment, and a single healthy spleen 
sample from an organ donor (HOD). Cells in the gates demarcated in 
A were analyzed for cell surface marker expression in before (n = 25) and 
after treatment (n = 19–24), and in HOD (n = 8) samples. The paired 
samples (n = 6) shown separately were also included in the group analyses. 
Percentages (B–E) and ratios (F and G) between analyzed subsets are 
shown. Signifi  cant differences are indicated with p-values in graphs.810  IL-10-PRODUCING SPLENIC T CELLS IN HUMAN VL | Nylén et al.
spleen size (Table I). Although no signifi  cant change in the 
CD4/CD8 T cell ratio pre- compared with posttreatment 
was observed, a posttreatment decrease in the percentage of 
CD3+CD4+ lymphocytes was apparent, whereas the eff  ect 
on CD3+CD8+ cells was less so (Fig. 5, E and F).
CD45RA/RO expression on CD4 cells did not change 
between pre- and posttreatment (not depicted). Less than 
3% of the splenic lymphocytes analyzed were NK cells 
(NKp46+CD3−), with no diff  erence between pre- and post-
treatment samples (not depicted). Plasma cells (CD138+) 
were only detectable at low levels in aspirates from 2 of 16 
patient samples analyzed. Expression of CD14, a monocyte-
associated cell surface marker, was evaluated in 14 patients 
before treatment, 11 patients after treatment, and 8 HOD 
samples and found to be low on the gated cells (before: 2.7 ± 
2.6%; after: 3.8 ± 4.4%; HOD: 2.5 ± 0.9%), with no signifi  -
cant diff  erences between the groups.
No accumulation of T reg cells in splenic aspirates 
from VL patients before treatment
In experimental and human hosts, tissue-specifi  c accumula-
tion or proliferation of T reg cells at sites of chronic infection 
or tumor metastasis has been observed (27–29). To test if 
  active VL is associated with accumulation of T reg cells in 
  lesional tissue, splenic aspirates were analyzed before and after 
treatment for CD4+CD25+ cells and expression of Foxp3 
mRNA (Fig. 6). On average, only 2.3% of the gated splenic 
lymphocytes, or 10% of the CD4+ cells, from VL patients 
with active VL were CD4+CD25+, with no diff  erence be-
tween pre- and posttreatment samples. Although CD25 ex-
pression correlates well to cells with regulatory activity in the 
blood, its usefulness as a marker of T reg cells at other sites has 
been questioned (29, 30). Nonetheless, splenic Foxp3 mRNA 
expression levels refl  ected the CD25 data, showing no sig-
nifi  cant diff  erence in VL patients before and after treatment 
(Fig. 6 B). Foxp3 mRNA was also not elevated in comparison 
with HODs, suggesting that the pretreatment samples did not 
refl  ect sustained elevated levels that had not yet returned to 
the   expression levels typical of a healthy spleen. Hence, there 
would not appear to be a selective recruitment or expansion 
of   T reg cells in the primary target organ of   VL patients dur-
ing active disease.
Cytokine mRNA expression in VL spleen
Real-time PCR analysis clearly indicated that IL-10 mRNA 
levels in splenic aspirates were, as anticipated, signifi  cantly higher 
in pre- compared with posttreatment and HOD spleen samples 
(Fig. 7). This diff  erence was refl  ected in 8 of 10 paired samples. 
As shown previously (7, 8), pretreatment   samples also expressed 
Figure 6.  Evaluation of natural T reg cells in VL spleen. (A) Fre-
quency of CD4+CD25+ cells as a percentage of gated splenic lymphocytes 
from VL patients before (n = 20) and after treatment (n = 19), and in 
HOD spleen samples (n = 8). (B) Relative expression of Foxp3 mRNA 
in splenic aspirates from VL patients before (n = 31) and after treatment 
(n = 12), and in HOD spleen samples (n = 8). Paired samples are included 
in groups but are also shown separately. Surface marker and Foxp3 
  expression analyses were not performed on the same VL patients.
Table I.  Aggregate clinical data for VL patients and ECs
VL (pretreatment)a VL (posttreatment) EC Control spleen
n 106 33 33 8
Age 22.3 ± 13 (19)b   23.4 ± 13.8 (19.5) 40.7 ± 13.5 (40) ND
Sex % (M/F) 70:30 80:20 59:41 ND
Duration of illness (mo) 2.1 ± 2.5 (1)   2.3 ± 2.7 (1.5) N/A N/A
Infection scorec   2 ± 1.2 (2) 1.8 ± 1.1 (1) N/A N/A
Spleen size (cm) Day 0 5.8 ± 4.3 (5) 5.7 ± 3.1 (6) N/A N/A
Day 15 2.9 ± 3.1 (2) 3.4 ± 2.8 (2) N/A N/A
WBC (×103/mm3) Day 0   3.1 ± 1.6 (2.7)    3 ± 1.4 (2.6) ND N/A
Day 15   4.9 ± 2.3 (4.7)   4.2 ± 1.8 (3.7) ND N/A
N/D, not done; N/A, not applicable.
aIncludes 30 donors from whom posttreatment samples were also available (column three).
bMean values ± SD of aggregated data are shown, and median values are given within parenthesis.
cScoring of parasite load is on a logarithmic scale from 1 to 6, were 0 is no parasites per 1,000 microscopic fi  elds (1,000×), 1 is 1–10 parasites per 1,000 fi  elds, and 6 is >100 
parasites per fi  eld.JEM VOL. 204, April 16, 2007  811
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signifi  cantly more IFN-γ mRNA than posttreatment samples. 
IL-4 mRNA was expressed only at very low levels in each of 
the groups, and along with TNF-α mRNA, it did not change 
with treatment. A slight elevation in TGF-β mRNA was 
  observed in the pretreatment samples. As this   cytokine is consti-
tutively expressed by many cell types, and bioactive TGF-β 
  requires posttranscriptional processing, the signifi  cance of this 
fi  nding is diffi   cult to assess. Finally, the   expression levels of 
CD3ε were similar in all groups, and   normalization with CD3ε 
did not change the results (not depicted).
Cellular source of IL-10 in the spleen
Because elevated pretreatment levels of IL-10 may be a key 
factor in the pathogenesis of VL, we were interested in which 
cells were responsible for IL-10 production. Analysis of posi-
tively selected splenic cell subsets obtained after sequential 
enrichment using CD19, CD25, and CD3 MACS beads 
showed no correlation between Foxp3 mRNA and IL-10 
mRNA expression. Although Foxp3 mRNA was, as ex-
pected, highly enriched in the positively selected CD25+ cells, 
IL-10 mRNA was expressed at the highest levels in the CD25-
  depleted, CD3+-enriched cells (Fig. 8, A–D). Moreover, 
FACS analysis together with morphological evaluation of 
splenic smears implicated CD3+ (CD25−) lymphocytes as a 
major cell subset in the aspirates (Fig. 4) and thus likely to be 
the main source of IL-10 mRNA in the VL spleen. Importantly, 
Figure 7.  Cytokine mRNA expression in VL spleen. Ex vivo analysis 
of relative cytokine mRNA levels in splenic aspirates from VL patients 
before (n = 31) or 21 d after treatment (n = 12), and in HOD spleen 
Table II.  Surface marker expression on PBMC lymphocytes
CD marker VL pretreatment 
(n = 22)
EC
(n = 23)
% of gated lymphocytesa
CD3+    56.7 ± 25.6 63.3 ± 14.1
CD19+   5.1 ± 3  6.1 ± 3.1
Ratio CD3/CD19   13.7 ± 7.8 14.8 ± 11
CD16+     6.5 ± 4.6b  10.1 ± 5.9
NKp46+ (n = 16/17)   3.5 ± 3b   6.1 ± 3.8
CD56+CD3− (n = 10)   3.25 ± 2.5   4.5 ± 1.7
% of gated CD3+ lymphocytes
CD4+   50.9 ± 9.9 46.6 ± 12
CD8+ 37.5 ± 9   41.8 ± 10.1
Ratio CD4/CD8    1.5 ± 0.7   1.2 ± 0.5
% of gated CD4+ lymphocytes
CD45RA     45 ± 17.1c 29.6 ± 9.6
CD45RO    47.6 ± 15.8d  71.2 ± 10.7
Ratio RA/RO   1 ± 1  0.4 ± 0.2
aLymphocytes were gated by forward side scatter, including blast/large cells.
bP < 0.05.
cP < 0.01.
dP < 0.001.
samples (n = 8). Paired samples (n = 10) are included in groups 
but are also shown separately. Signifi  cant differences are indicated 
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a signifi  cant decrease in IL-10 mRNA levels within the CD3+ 
(CD25−) subset was observed after treatment (Fig. 8 D), re-
fl  ecting the decrease in paired samples when whole aspirates 
were compared (Fig. 7).
The same subset was also the main source of IFN-γ 
mRNA expression, and a similar decrease was seen in IFN-γ 
mRNA levels with treatment (Fig. 8, E and F). Real-time 
PCR of CD3ε mRNA was included to monitor the enrich-
ment of T cells in the samples because there was not suffi   cient 
numbers of selected cells to analyze by FACS. CD3ε mRNA 
expression was highest in the CD3+ selected cells. However, 
CD3ε expression was signifi  cantly lower in the CD25+ cells 
than in the CD3+ cells, which could refl  ect down-regulation 
of CD3ε expression, but it could also indicate that the se-
lected CD25 cells are not a pure T cell population. Using a 
similar positive selection protocol on PBMCs, we found that 
85–90% of the selected CD25+ cells were T cells (CD3+). In 
any event, as the CD25+ population was clearly enriched for 
cells expressing Foxp3, then if natural T reg cells were a major 
source of IL-10, they should also be enriched for IL-10 
mRNA, and this was not the case. And although the CD3+ 
CD25-depleted population appeared to contain a signifi  cant 
number of Foxp3+ cells relative to the CD19+ and “depleted” 
fractions, these cells are unlikely to contribute substantially to 
the high levels of IL-10 mRNA in this population because 
this would again be refl  ected by a strong association of IL-10 
within the Foxp3-enriched CD25+ cells.
The depleted, negatively selected population remaining 
  after the removal of CD19+, CD25+, and CD3+ cells expressed 
signifi  cantly less IL-10 mRNA compared with the positively 
selected CD3+ population (P = 0.0273). Cell surface pheno-
typing of fi  ve depleted samples that contained suffi   cient 
  numbers of cells for FACS analysis revealed a heterogenous 
population of cells and essentially confi  rmed the Foxp3 and 
Figure 8.  Ex vivo analysis of mRNA expression in splenic lympho-
cyte subsets. Relative expression of Foxp3 (A and B), IL-10 (C and D), 
IFN-γ (E and F), and CD3ε (G and H) mRNA in sequential, positively selected 
CD19+, CD25+, and CD3+ cells, and in the remaining depleted spleen cell 
populations before treatment (n = 16; A, C, E, and G). mRNA expression 
in pre- and posttreatment paired samples (n = 7) enriched for CD3+ 
(CD19, CD25 depleted) spleen cells (B, D, F, and H). Signifi  cant differences 
are indicated with p-values.JEM VOL. 204, April 16, 2007  813
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CD3ε mRNA expression analysis, indicating that while the 
CD25+ cells had been effi   ciently removed, CD3+ cells were 
still present (22 ± 7% of gated lymphocytes), although much 
reduced compared with the whole splenic aspirates.
DISCUSSION
Elevated production of IL-10 has also been a consistent fi  nd-
ing in human VL (6–8, 26, 31, 32) and is reinforced in the 
present studies with respect to the levels detected in plasma 
and spleen. IL-10 is presumed to play a determinant role in 
the pathogenesis of VL based on experimental models in 
which IL-10–defi  cient or anti–IL-10 receptor–treated mice 
display enhanced resistance or clinical cure (11, 13) and re-
ports that anti– IL-10 treatment may revert the antigen-spe-
cifi  c unresponsiveness of PBMCs from VL patients in vitro 
(33, 34). Importantly, the source of IL-10 in human VL is not 
known. As IL-10 produced by naturally occurring T reg cells 
has been shown to promote chronic infection in mouse mod-
els of cutaneous leishmaniasis (17, 27), and as accumulating 
fi  ndings pertaining to chronic infections in humans have im-
plicated natural T reg cells in the down-modulation of pro-
tective immunity (18, 22, 23, 35), the primary objective of the 
present studies was to evaluate the contribution of natural T 
reg cells to IL-10 production in human VL and their associa-
tion with the pathogenesis of this disease. The extensive data 
generated, however, does not support a major role for natural 
T reg cells in human VL. Active disease was not associated 
with a higher frequency of CD4+CD25+ T cells or higher 
expression of Foxp3 in the blood or a target organ, the spleen. 
Moreover, depleting PBMCs of CD25+ cells did not recon-
stitute antigen-specifi  c IFN-γ responses. Importantly, natural 
T reg cells did not appear to contribute to the elevated lev-
els of IL-10 present in the VL spleen. Instead, the main source 
of IL-10 was identifi  ed as a T cell population depleted of 
CD25+Foxp3high cells, a fi  nding that implicates adaptive T reg 
cells in the immunosuppression of potentially curative anti-
leishmanial responses in kala-azar.
Prior studies characterizing T cell responses in kala-azar 
have been confi  ned to peripheral blood, from which an ade-
quate number of lymphocytes can be routinely obtained for 
T cell subset purifi  cation, depletion, and functional analyses. 
The present studies are the fi  rst to address the potential con-
tribution of natural T reg cells to the antigen-specifi  c unre-
sponsiveness observed in PBMCs from VL patients. If anything, 
the results point to a loss of T reg cells and T reg function in 
the blood. A lower frequency of CD4+CD25+CD45RO+ 
cells was observed, and expression of Foxp3 was slightly lower 
in whole PBMCs from VL patients compared with ECs. Fur-
thermore, CD25 depletion, although clearly unable to recon-
stitute the antigen-specifi  c response, also did not signifi  cantly 
enhance the SEB-induced IFN-γ response in VL patients 
as it did in the PBMCs from ECs. However, removal of 
CD25+ cells from PBMCs did reduce the SEB-induced IL-
10 production in PBMCs from both EC and VL patients, 
confi  rming that T reg cells may be an important physiologic 
source of IL-10, particularly if there is selective recruitment, 
activation, or expansion of T reg cells in target organs such as 
the spleen.
Despite the limiting cell numbers in residual splenic aspi-
rates available for study, the submission of the cells to pheno-
typic characterization by FACS, sequential subset purifi  cation, 
and cytokine mRNA expression profi  ling by real-time PCR 
yielded remarkably consistent fi  ndings regarding the associa-
tion of specifi  c cells and cytokines to VL pathology. Mor-
phologic, together with fl  ow cytometric, analysis of splenic 
aspirates indicated that T cells were the main leukocyte subset 
in VL patients before treatment, consistent with prior obser-
vations (25). This is in contrast to healthy donors in whom B 
cells appear to dominate the spleen (Fig. 5 and reference 36). 
Thus, similar to what has been observed in experimental VL 
(37), T cells, including CD4+ T cells with specifi  city for het-
erologous antigens (38), may accumulate in the VL spleen. 
There did not appear to be selective recruitment or expan-
sion of T reg cells, as the frequency of CD4+CD25+ T cells, 
or the expression of Foxp3 mRNA, was not signifi  cantly in-
creased in the VL spleen. Much of the splenic response ap-
pears to be proinflammatory, as indicated by the elevated 
splenic transcript levels of IFN-γ and the elevated plasma 
protein levels of IFN-γ, IL-12, IL-6, and TNF-α. These clini-
cal fi  ndings indicate that unfavorable infection outcomes are 
not related to Th2 dominance or a Th1 response defect per se, 
but to concomitant production of counterregulatory cyto-
kines, in particular IL-10, that may be triggered as a homeo-
static response to limit immune-mediated pathology.
The results clearly showed that on a population basis 
comparing diff  erent subsets of positively selected splenic cells, 
and normalized for levels of 18S mRNA, CD25+ cells ex-
pressed signifi   cantly less IL-10 mRNA than the CD3+ 
CD25-depleted cells, and Foxp3 expression did not correlate 
with IL-10 expression. Gene expression of Foxp3 and CD3ε 
was used as a control for enrichment because there was insuf-
fi  cient material to perform FACS analysis on the positively 
selected cells. The cells that appeared to be the most impor-
tant source of IL-10, both on a population basis comparing 
roughly equivalent numbers of positively selected cells and 
taking into account the relative frequencies of cells in the 
whole aspirate, were the CD3+ CD25-depleted cells, which 
by far out number the CD25+ cells in the VL spleen.
Previous reports, based primarily on fi  ndings in L. major–
infected BALB/c mice (24), have suggested monocytes/
macrophages as an important source of IL-10 in VL, and 
examination of lymphoid organs of VL patients has revealed 
an increase in the number of these cells (39–41). Our analysis 
cannot exclude that VL may produce changes in the frequen-
cies of splenic macrophages or that these cells secrete high 
levels of IL-10. Macrophages, however, represented only a low 
percentage of the cells in the aspirates we scored. Moreover, 
IL-10 mRNA expression in the negatively selected splenic 
population depleted of CD19+, CD25+, and CD3+ cells was 
signifi  cantly lower compared with the positively selected 
CD3+ cells. Although this population still contained a sub-
stantial number of lymphocytes, it was presumably enriched 814  IL-10-PRODUCING SPLENIC T CELLS IN HUMAN VL | Nylén et al.
for monocytes/macrophages. Collectively, these results do not 
implicate monocytes/macrophages as the main source of 
splenic IL-10. It should be noted that the patients included in 
this study mostly had a low parasite burden and had only ex-
perienced symptoms of VL for 1–2 mo when splenic aspirates 
were obtained for diagnosis. Thus, in comparison with other 
studies, our data may refl  ect an earlier phase of the disease. 
The fi  nding that splenic accumulation of CD25−Foxp3− T 
cells expressing elevated levels of IL-10 mRNA occurs at a 
relatively early stage of disease argues that it is not simply a 
secondary outcome of chronic exposure to high parasite bur-
dens in the spleen, but it may be causally related to the evolu-
tion of the noncure response.
We have been unable to demonstrate that IL-10 is di-
rectly responsible for Leishmania-specifi  c unresponsiveness of 
PBMCs in vitro, as we were unable to rescue antigen-induced 
proliferation or IFN-γ production in the presence of anti–IL-
10 antibodies, even when cultures were optimized for T cell 
activation using antigen-pulsed or infected autologous den-
dritic cells. Although anti–IL-10 antibodies have been found 
to promote these responses in two prior studies of VL, the num-
ber of patients studied were small, the eff  ects were modest, 
and/or control antibodies were not compared (6, 33). It is 
possible that the peripheral blood of Indian VL patients dur-
ing their early stage of disease is relatively depleted of anti-
gen-specifi  c cells, which are recruited to and accumulate in 
lesional tissue. Our studies confi  rm that the splenic Foxp3− T 
cells are enriched for and express elevated levels of IFN-γ 
mRNA. It has so far not been feasible to examine the infl  u-
ence of IL-10 on antigen-specifi  c responses in the few splenic 
cells available for analysis. Our studies strongly suggest, how-
ever, that apart from suppressing the generation or mainte-
nance of a Th1 response, the main disease-promoting activity 
of IL-10 might be to condition host macrophages for en-
hanced survival and growth of the parasite. A fi  vefold dilu-
tion of VL plasma from each of 13 patients tested showed an 
IL-10–dependent enhancement of L. donovani intracellular 
growth in human macrophages. The consequences of pro-
longed exposure to elevated, circulating levels of IL-10 on 
promoting intracellular parasitism, and impairing the ability 
of macrophages to kill in response to activation signals, is apt 
to be substantial.
Based on the results presented here, we propose that T 
cells, variably referred to as adaptive T reg or Tr1 cells (42), 
that arise from CD25−Foxp3− T cells in the periphery, are 
antigen driven, and can produce large amounts of IL-10, are 
more important than naturally occurring T reg cells in the 
suppression of anti-leishmanial immunity in human VL. As 
the CD3+ CD25-depleted fraction was also enriched for the 
cells producing IFN-γ in the spleen, it is possible that at least 
some of the cells produce both cytokines. Simultaneous pro-
duction of IFN-γ and IL-10 by human T cell clones can be 
induced by IL-12 (43), and T cell subsets secreting both cy-
tokines have been described in mice infected with L. major 
(44, 45) or Toxoplasma gondii (46), and in humans infected 
with Borrelia burgdorferi (47) or Mycobacteria tuberculosis (48).
 Antigen-specifi   c, IL-10–producing T reg cells arising 
from CD25−Foxp3− cells have been described in several ex-
perimental systems involving, for example, immunosuppres-
sive drugs or repeated administration of an antigenic peptide 
(41, 49). They are critical in regulating colitis induced by Helico-
bacter hepaticus infections in mice (50) and are thought to regu-
late immune responses in tuberculosis patients (51). Most 
critically, IL-10 production by splenic CD4+CD25−Foxp3− 
cells has recently been associated with disease progression in 
L. donovani–infected mice (52), and CD25−Foxp3− CD4 T 
cells have been shown to be the critical source of IL-10–
  mediated suppression in chronic cutaneous murine leishmaniasis 
(44). As recently proposed (53), IL-10–producing adaptive T 
reg cells may be preferentially induced and required to con-
trol tissue damage in sites of strong infl  ammation associated 
with antimicrobial responses. Therapies that specifi  cally target 
IL-10–producing T reg cells, or directly inhibit IL-10 func-
tion, might shift the balance of eff  ector and regulatory cyto-
kines to favor immune clearance of the parasite and enhance 
the effi   cacy of current drugs against VL.
MATERIALS AND METHODS
Study subjects. Aggregated clinical data for the patients and ECs enlisted in 
this study are provided in Table I. All patients presented with symptoms at the 
Kala-azar Research Center, Muzaff  arpur, Bihar, India, and were confi  rmed to 
be VL+ by detection of amastigotes in splenic aspirates and/or by detection 
of antibodies against the recombinant antigen, K39 (54). Patients positive for 
HIV were excluded from the study. In total, 106 patients were included in 
the study. Their median and average duration of illness were 1 and 2.1 mo, 
respectively, with a median/average splenic infection score of 2.
Splenic needle aspirates were collected for diagnostic purposes before 
treatment and 3–4 wk after initiation of Amphotericin B treatment to evalu-
ate parasitologic cure. Venous blood (heparinized) was obtained from adult 
VL patients (16 yr and older) before treatment and from EC volunteers (n = 33), 
who were in each case healthy adult household family members of an active 
case. Control healthy spleen cells (n = 8), obtained from necro organ trans-
plantation donors (HODs) at Karolinska University Hospital, Huddinge, 
Stockholm, Sweden, were isolated on a Ficoll gradient, frozen in 10% DMSO, 
90% FCS, and stored at –150°C until used. The study of human volunteers 
followed recommendations outlined in the Helsinki Declaration. Ethical ap-
proval for the study was obtained from appropriate institutional review com-
mittees in India, Sweden, and the United States.
Detection of cytokines in plasma. Plasma levels of IL-2, IL-4, IL-6, IL-10, 
IL-12p40, IL-12p70, IL-13, IFN-γ, TNF-α, and TGF-β were measured by 
Pierce Biotechnology/Perbio Science multiplex sample analysis service.
Biological activity of plasma IL-10. The eff  ect of human plasma from VL 
patients and ECs on intracellular infection was assayed using human macro-
phages generated from CD14+ peripheral blood–derived monocytes ob-
tained from a normal donor, as described previously (55). Macrophages were 
plated in eight-chamber Lab-Tek Permanox tissue culture slides (Nalge 
Nunc) at 105 cells/well in a volume of 0.4 ml RPMI 1640 complete. Hamster-
derived tissue-purifi   ed amastigotes of L. donovani strain 9515 (MHOM/
IN/95/9515), isolated from a patient with VL in Bihar, India, were added to 
macrophages at a 2:1 ratio and incubated for up to 6 h at 35°C. Remaining 
extracellular parasites were removed by extensive washing, and the infected 
cells were incubated for an additional 72 h in complete RPMI containing 
20% human plasma and either 20 μg/ml anti–IL-10 (MAB2171) or IgG2b 
isotype control (MAB004) antibodies. Recombinant human IL-10 was used 
at 10 ng/ml (all from R&D Systems). Slides were stained with Diff  -Quik 
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calculated based on the percent of macrophages infected and the number of 
amastigotes per infected cell. All conditions were performed in duplicate, and 
at least 300 cells were counted for each culture.
Real-time PCR. Whole splenic needle aspirates ( 100–150 μl) were di-
rectly placed in 1 ml RNAlater (QIAGEN) and stored at –70°C until used. 
Total RNA was isolated using the RNeasy minikit and Qiashredder homog-
enizers (QIAGEN) according to the manufacturer’s protocol. Quality of 
RNA was assessed by denaturing agarose gel electrophoresis and ethidium 
bromide staining. Reverse transcription was performed in 40-μl reactions on 
0.1–0.4 μg RNA (samples compared were of the same concentrations) using 
Superscript III First-Strand synthesis system for RT-PCR (Invitrogen) ac-
cording to the manufacturer’s instructions.
To isolate RNA from selected lymphocyte subsets, the viability of cells 
in the splenic aspirates were maintained during the 18–24-h transportation 
period in chilled heparinized tubes containing 1 ml RPMI 1640 supple-
mented with 10% normal human AB+ serum and 5 U/ml IL-2 (Sigma-
  Aldrich). Thereafter, erythrocytes were lysed by a 5-min incubation in cold 
ACK-lysis buff  er, washed with PBS, and diluted in PBS containing 0.5% 
BSA and 2 mM EDTA. Cell subsets were enriched by sequential positive se-
lection of CD19+ cells, followed by CD25+ cell selection from the CD19-
depleted fraction and CD3+ cell selection from the CD19- and CD25-depleted 
cells using MACS beads and MS columns (Miltenyi Biotec) according to the 
manufacturer’s instructions, but using twice the volume of CD19 beads. Cells 
remaining after the removal of CD19+, CD25+, and CD3+ cells are referred 
to as depleted. The positively selected and the depleted cells were resus-
pended in 25–50 μl PBS, followed by mixing with 200–300 μl RNAlater. 
They were stored at –70°C until used. RNA was isolated as described above, 
except that the isolated cell subsets were processed as liquid samples. Real-
time PCR was performed on an ABI Prism 7900HT sequence detection 
system (Applied Biosystems) using cDNA-specifi  c FAM-MGB–labeled 
primer/probe sets for Foxp3, IFN-γ, IL-10, IL-4, TGF-β, and TNF-α with 
VIC-MGB–labeled 18S mRNA (primer limited) as control for the relative 
amount of mRNA in each sample. CD3ε expression was measured using the 
same method and used as an estimate of the varying percentages of T cells 
in pre- and posttreatment samples. All reagents were purchased from Applied 
Biosystems. The relative quantifi  cation of products was determined by the 
number of cycles over 18S mRNA endogenous control required to detect 
the gene expression of interest.
Analysis of cell surface marker expression. PBMCs were purifi  ed by 
Ficoll-Hypaque (Amersham) gradient centrifugation. Splenic aspirates were 
collected in 1 ml RPMI 1640 supplemented with 10% normal human AB+ 
serum and 5 U/ml IL-2 (Sigma-Aldrich). The red blood cell content was re-
duced by a 5-min incubation in cold ACK lysis buff  er. PBMCs and spleen 
cells from EC and/or VL patients were stained with combinations of the 
  following fl  uorochrome-labeled antibodies: CD3-FITC or PECy5, CD4-
PECy5, CD8-PECy5 or allophycocyanin (APC), CD14-PE, CD16-FITC, 
CD19-APC, CD45RA-FITC, CD45RO-APC, CD56–Alexa 488, NKp46-
PE, CD138-FITC (BD Biosciences), and CD25-PE (Miltenyi Biotec). HOD 
spleen cells were stained with CD3-APC, CD4-FITC, CD14-FITC, CD19-
PE (BD Biosciences), and CD25-PE (Miltenyi Biotec). Fluorescence was 
measured on lymphocytes and blast cells gated by forward (linear scale) and 
side (log scale) light scatter using FACSCalibur and CELLQuest software 
(BD Biosciences).
Cell culture. Whole PBMCs or PBMCs depleted of CD25 cells (MACS) 
were cultured for 3 d with 25 μg/ml SLA (prepared as described previously 
[56]), 10 μg/ml SEB, or in the absence of antigen. Dendritic cells were gen-
erated from CD14+ peripheral blood–derived monocytes as described previ-
ously (55). Anti–IL-10 and isotype control antibodies were used at 10 μg/ml 
and recombinant human IL-10 was used at 10 ng/ml. Production of IL-10 
and IFN-γ was measured in culture supernatants by ELISA (MabTech) ac-
cording to the manufacturer’s instructions. The detection limits for IFN-γ 
ranged from 15 to 30 pg/ml and for IL-10 from 30 to 60 pg/ml.
Statistical analysis. Statistical signifi  cances were analyzed using PRISM4 
(GraphPad Software). Diff  erences between groups or paired pre- and post-
treatments were compared by two-tailed t test for unpaired and paired sam-
ples, respectively. Mann-Whitney U-test was applied if samples did not pass 
a normality test.
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